CHF88.44
5.80% today
SIX Swiss Exchange, Apr 03, 05:20 pm CET
ISIN
CH1335392721
Symbol
GALD
Sector
Industry

Galderma Target price 2025 - Analyst rating & recommendation

Galderma Classifications & Recommendation:

Buy
75%
Hold
25%

Galderma Price Target

Target Price CHF113.64
Price CHF93.89
Potential
Number of Estimates 11
11 Analysts have issued a price target Galderma 2026 . The average Galderma target price is CHF113.64. This is higher than the current stock price. The highest price target is
CHF123.95 32.01%
register free of charge
, the lowest is
CHF105.14 11.98%
register free of charge
.
A rating was issued by 12 analysts: 9 Analysts recommend Galderma to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Galderma stock has an average upside potential 2026 of . Most analysts recommend the Galderma stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Billion CHF 3.88 4.29
5.88% 10.40%
EBITDA Margin 21.34% 22.60%
2.16% 5.91%
Net Margin 5.26% 8.56%
469.20% 62.83%

11 Analysts have issued a sales forecast Galderma 2025 . The average Galderma sales estimate is

CHF4.3b
Unlock
. This is
10.38% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF4.3b 11.26%
Unlock
, the lowest is
CHF4.2b 9.40%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF3.9b 5.88%
2025
CHF4.3b 10.40%
Unlock
2026
CHF4.9b 14.71%
Unlock
2027
CHF5.7b 15.18%
Unlock
2028
CHF6.2b 8.91%
Unlock
2029
CHF6.8b 9.94%
Unlock

11 Analysts have issued an Galderma EBITDA forecast 2025. The average Galderma EBITDA estimate is

CHF969m
Unlock
. This is
16.98% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF994m 19.95%
Unlock
, the lowest is
CHF896m 8.14%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF829m 8.17%
2025
CHF969m 16.93%
Unlock
2026
CHF1.2b 26.42%
Unlock
2027
CHF1.5b 24.93%
Unlock
2028
CHF1.8b 19.47%
Unlock
2029
CHF2.1b 16.75%
Unlock

EBITDA Margin

2024 21.34% 2.16%
2025
22.60% 5.91%
Unlock
2026
24.91% 10.22%
Unlock
2027
27.02% 8.47%
Unlock
2028
29.64% 9.70%
Unlock
2029
31.47% 6.17%
Unlock

8 Galderma Analysts have issued a net profit forecast 2025. The average Galderma net profit estimate is

CHF367m
Unlock
. This is
81.93% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
CHF405m 100.71%
Unlock
, the lowest is
CHF324m 60.37%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 CHF204m 490.91%
2025
CHF367m 79.81%
Unlock
2026
CHF636m 73.36%
Unlock
2027
CHF904m 42.09%
Unlock
2028
CHF1.2b 33.00%
Unlock
2029
CHF1.5b 21.08%
Unlock

Net Margin

2024 5.26% 469.20%
2025
8.56% 62.83%
Unlock
2026
12.94% 51.17%
Unlock
2027
15.96% 23.34%
Unlock
2028
19.50% 22.18%
Unlock
2029
21.47% 10.10%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share CHF 0.86 1.55
490.91% 80.23%
P/E 60.72
EV/Sales 5.68

8 Analysts have issued a Galderma forecast for earnings per share. The average Galderma EPS is

CHF1.55
Unlock
. This is
82.35% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
CHF1.71 101.18%
Unlock
, the lowest is
CHF1.36 60.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 CHF0.86 490.91%
2025
CHF1.55 80.23%
Unlock
2026
CHF2.68 72.90%
Unlock
2027
CHF3.81 42.16%
Unlock
2028
CHF5.07 33.07%
Unlock
2029
CHF6.13 20.91%
Unlock

P/E ratio

Current
2025
60.72 44.93%
Unlock
2026
35.02 42.33%
Unlock
2027
24.65 29.61%
Unlock
2028
18.53 24.83%
Unlock
2029
15.31 17.38%
Unlock

Based on analysts' sales estimates for 2025, the Galderma stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 6.28
2025
5.68 9.48%
Unlock
2026
4.96 12.83%
Unlock
2027
4.30 13.18%
Unlock
2028
3.95 8.18%
Unlock
2029
3.59 9.04%
Unlock

P/S ratio

Current
2025
5.20 9.41%
Unlock
2026
4.53 12.83%
Unlock
2027
3.93 13.18%
Unlock
2028
3.61 8.18%
Unlock
2029
3.29 9.04%
Unlock

Current Galderma Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
BERENBERG
Locked
Locked
Locked Nov 25 2024
BNP PARIBAS EXANE
Locked
Locked
Locked Aug 21 2024
Analyst Rating Date
Locked
BERENBERG:
Locked
Locked
Nov 25 2024
Locked
BNP PARIBAS EXANE:
Locked
Locked
Aug 21 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today